The world's first case! Immune cell therapy completely cures cervical cancer
- Apr 03, 2018 -

Cervical cancer is one of the most common gynecological malignancies. According to World Health Organization estimates, there are 500,000 new cervical cancer cases each year in the world. About 200,000 women die each year from cervical cancer. There are about 131,000 new cervical cancers in China each year. Incidence cases account for 28.8% of new cases worldwide. In recent years, the incidence and mortality of cervical cancer have been young. The incidence of women under 35 has increased significantly. The incidence rate has risen from 5% to 10%, accounting for about one-third of new cases.

At this stage, the treatment of cervical cancer will be based on clinical stages, patient age, fertility requirements, general conditions, medical technology and equipment conditions and other comprehensive consideration to develop appropriate individualized treatment plan, and the use of surgery and radiotherapy, chemotherapy-assisted In recent years, immunotherapy that has demonstrated a powerful anti-cancer effect in various cancers has also been reported in the treatment of cervical cancer.

Recently, US researchers successfully used immunotherapy to completely cure a patient with cervical cancer, and have not relapsed for 5 years. This is the first case in the world to use immunotherapy to cure cervical cancer.

It is understood that the cured cervical cancer patient from the United States, named Sue Scott, is 36 years old. Before the immunotherapy, Scott has had multiple rounds of chemotherapy, radiotherapy, and surgery, but all failed. Scott's cancer cells spread. Very quickly, she has invaded her liver and colon and squeezed her ureter.

Subsequently, Scott participated in an immunotherapeutic trial organized by the National Institute of Health Clinical Center (one of the most important research institutes in life sciences in the world). In this experiment, the doctor surgically removed some of her tumors. The immune T cells were isolated and the researchers modified and expanded these tumor-infiltrating lymphocytes (TILs) and reinjected them into the body to form an immune force that targeted and attacked cancer cells, eventually killing the cancer cells.

The results of the trial were unexpected. After a few months, Scott's tumor completely disappeared. In March 2018, she celebrated the 5th anniversary of cancer rehabilitation. The doctor told her that her cancer had completely cured.

Christian Hinrichs, chief researcher at the National Cancer Institute in the United States, said: "We got this gene sequence from Scott and now we can put it in anyone's cells and make them attack cancer cells in the same way. This is a special Surprising news.

In addition, in the same group of trials Scott participated in, there was a 41-year-old mother Aricca Wallace also passed a five-year survival period, but the treatment of 16 other women patients failed.

In order to clarify the reasons for the above results, the research team headed by Hinrichs conducted another study of the cells injected into Scott and Wallace. The researchers found that these cells actually targeted HPV, but in the case of Wallace, most of the T cells Focused on destroying the abnormal proteins that are unique to her tumors. In Scott's case, about two-thirds of T cells target another target, the KK-LC-1 protein, which is also found in other common tumors. Expression, such as triple negative breast, certain gastric cancer, non-small cell lung cancer.

As a result, the researchers discovered a new target, and Hinrichs' team hopes to develop a clinical therapy for tumors expressing KK-LC-1 protein within one year.